Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Upcoming GU cancer trials to be presented at ESMO 2022

Nicholas James, MBBS, PhD, FRCP, FRCR, The Royal Marsden NHS Foundation Trust, London, UK, comments on key trials that will be presented in the field of prostate cancer at this year’s European Society for Medical Oncology (ESMO) 2022, including the Phase III RADICALS trial (NCT00541047). The study aims to assess the administration of adjuvant radiotherapy in patients with relapsed prostate cancer, as well as the role of hormone therapy in this group of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.